|
Key Takeaways:
|
Thyroid eye disease (TED) is an autoimmune condition where inflammation builds up around the eyes and slowly changes delicate eye tissues. It can start with dryness and a “staring” look, but in some people it can progress to double vision, exposure problems, or even optic nerve pressure. The good news is that timing matters. When TED is caught and treated early, doctors can protect the eye surface and reduce the chance of long-term tissue damage.
In this blog, we will talk about what is thyroid eye disease (TED), causes, what it damages in the eye and how, symptoms to look for, diagnosis, and available treatment options.
What is Thyroid Eye Disease?
Thyroid eye disease (also called Graves’ orbitopathy) is an immune-driven condition where your immune system mistakenly targets tissues around the eyes, especially the extraocular muscles and orbital fat. This causes swelling, thickening, and later scarring, which changes how your eyes look and move.
TED is most commonly linked with Graves’ disease. About one in three people with Graves’ develop eye symptoms, while medical reviews commonly cite ~25–50% showing clinically apparent eye involvement.
Causes of Thyroid Eye Disease?
TED happens because of an immune “cross-reaction.” Some immune signals and antibodies that affect the thyroid also activate cells in the tissues around the eye. Those activated cells then produce substances that pull in water and create swelling, and later lead to fibrosis (scarring).
Smoking is one of the strongest and most consistent risk factors for TED, and it also makes treatment responses weaker. One classic study reported an odds ratio of 7.7 for thyroid-associated orbitopathy in smokers.
How Tissue Damage Happens in TED?
Think of the eye socket (orbit) like a small room with fixed walls. The eyeball sits in that room along with muscles, fat, nerves, and connective tissue. In TED, inflammation makes the muscles and fat swell, but the bony orbit cannot expand much, so pressure builds.
For example, if TED swelling pushes the eye forward, your eyelids do not close fully at night. That leaves the cornea exposed, like leaving a contact lens out in the air, so the surface dries, scratches, and becomes inflamed.
Stages of Thyroid Eye Disease
Over time, the TED follows two broad phases:
- Active (inflammatory) phase:
Swelling and redness are “alive,” symptoms can change quickly; many sources describe this lasting about 6–18 months and sometimes up to 6–24 months.
- Inactive (fibrotic) phase:
Inflammation cools down, but tissues may be left stiffer, thicker, and scarred, which is why some changes don’t fully reverse.
Which Eye Tissues Can TED Damage?
Below is a tissue-by-tissue map of what can change in TED, what that means, and what you might notice.
|
Tissue affected |
What changes in TED? |
What do you notice? |
Why does it matter? |
|
Eyelids/soft tissue |
Swelling, lid retraction, incomplete closure |
Puffy lids, “stare,” gritty eyes |
More exposure → dryness and corneal risk |
|
Cornea |
Exposure dryness, surface injury |
Burning, foreign body sensation, blurred vision |
Severe exposure can threaten vision |
|
Extraocular muscles |
Swelling then scarring |
Double vision, eye movement pain |
Can become long-term motility problem |
|
Orbital fat/connective tissue |
Expansion + inflammation |
Bulging eye (proptosis), pressure |
Increases exposure and crowding in orbit |
|
Optic nerve |
Compression (DON) |
Dim vision, color dullness, field loss |
Sight-threatening emergency |
Eyelids and Surrounding Soft Tissue
The eyelids and surrounding soft tissues damages and consequences:
Damage/changes:
- Lid swelling happens because inflamed tissues hold extra fluid. This is why mornings can feel worse.
- Upper lid retraction (lid sits higher than normal) creates the classic “wide-eyed stare.”
- Incomplete eyelid closure (lagophthalmos) can happen when the eye bulges forward or lids retract.
Consequences:
- More eye surface is exposed to air → dry eye, burning, watering, and irritation that keeps coming back.
- Night-time exposure can quietly damage the cornea while you sleep, especially if your lids don’t fully close.
Cornea (Clear Front Surface of the Eye)
The cornea damages and consequences:
Damage/changes:
- Exposure keratopathy, the cornea dries out because the lids don’t cover it well, or the tear film becomes unstable.
- Surface breakdown can occur in severe cases, tiny scratches can turn into more serious defects if dryness is strong and persistent.
Consequences:
- Light sensitivity, gritty pain, fluctuating blur, and redness that feels “surface-level.” A dry cornea is like a dry windshield, every blink becomes a wipe on a rough surface, so vision fluctuates and discomfort builds through the day.
- In severe exposure, corneal damage can become vision-threatening and requires urgent care.
Extraocular Muscles (Eye Movement Muscles)
The extraocular muscles damages and consequences:
Damage/changes:
- Muscles become swollen and inflamed in active TED, and later can become fibrotic (scarred) and less flexible.
- Inflammation can cause pain with eye movement, especially when looking up or sideways.
Consequences:
- Double vision (diplopia) because the eyes don’t move together smoothly anymore.
- Persistent scarring can leave long-term misalignment even after swelling settles, which is why timing of treatment matters.
Orbital Fat and Connective Tissue (Behind the Eye)
The orbital fat and connective tissue damages and consequences:
Damage/changes:
- Orbital fat and soft tissues can expand and hold water, increasing “volume” behind the eye.
- This extra volume pushes the eye forward → proptosis (bulging).
Consequences:
- More exposure → more dryness and corneal risk.
- Tight orbit crowding can increase pressure and, in severe cases, contribute to optic nerve compression.
Optic Nerve (Vision-Critical Tissue)
The optic nerve damages and consequences:
Damage/changes:
- The most serious complication is dysthyroid optic neuropathy (DON), the optic nerve gets compressed at the back of the orbit, by enlarged muscles and congestion.
- DON is not common, but it is sight-threatening. Reviews commonly cite an incidence around 5–8% in TED.
Consequences:
- Reduced vision, washed-out colors, or a “dim” look to vision in one or both eyes.
- Field loss can occur, and delay in treatment can risk permanent damage. This is a medical emergency.
Symptoms of Thyroid Eye Disease (TED)
Below are the common and serious symptoms of thyroid eye disease (TED):
Common Symptoms
These reflect eyelid/soft tissue and surface involvement:
- Dryness, burning, grittiness, watering
- Redness, swelling of eyelids
- Feeling of pressure behind the eyes
- Light sensitivity
- Eyes that look more open or “staring”
Serious Symptoms
These can suggest muscle restriction or optic nerve risk and should be assessed quickly:
- New or worsening double vision
- Pain with eye movement
- Eye bulging that is progressing
- Vision becoming dim or blurred, especially if it doesn’t clear with blinking
- Colors looking less bright in one eye
- Any rapid change in vision
Diagnosis of Thyroid eye disease (TED)
Diagnosis combines clinical history, examination, thyroid evaluation, and sometimes imaging.
- Eyelid position and swelling (including lagophthalmos)
- Eye surface and tear film (cornea health)
- Proptosis measurement (with exophthalmometry)
- Eye movements and diplopia assessment
- Visual acuity, color vision, pupil responses, visual fields if DON is suspected
- Thyroid blood tests (endocrinology-guided)
- Imaging (CT/MRI orbit) if disease is moderate-to-severe, atypical, or optic nerve compression is suspected
|
Clinical Activity Score (CAS) CAS is a checklist of pain and inflammation signs. A commonly used definition is that CAS ≥3 on a 7-point scale suggests active TED. Some examples of CAS items include: pain/pressure around the eye, pain on eye movement, lid swelling/redness, conjunctival redness, and chemosis (conjunctival swelling). |
Treatment Options For Thyroid Eye Disease (TED)
TED treatment is “layered.” Doctors match treatment to severity, activity, and which tissues are at risk.
Foundation steps that protect the cornea:
These matter at every stage because the cornea is the first tissue to suffer:
- Lubricating drops/gel to support the tear film and reduce surface micro-injury.
- Night-time ointment or taping if lids don’t close fully (prevents sleeping with an exposed cornea).
- Sunglasses and wind protection because exposed eyes dry faster in moving air.
Reduce inflammation in active TED:
Lowering inflammation early can reduce swelling pressure in the orbit and protect the cornea and optic nerve. For moderate-to-severe active TED, guidelines recommend intravenous methylprednisolone (IVMP) as more effective and better tolerated than oral steroids.
The EUGOGO 2021 guideline describes an optimal regimen as a cumulative 4.5 g IVMP in 12 weekly infusions, and also notes first-line combination with mycophenolate in many cases.
Targeted biologic therapy
Teprotumumab (IGF-1R inhibitor) has shown meaningful improvements in proptosis and symptoms in clinical trials. In a Phase 3 trial, 83% of patients had a proptosis response at 24 weeks versus 10% on placebo (response defined as ≥2 mm reduction).
When vision is threatened?
If dysthyroid optic neuropathy (DON) is suspected, treatment becomes urgent. When medical therapy fails or if compression is severe, orbital decompression can be used to relieve pressure on the optic nerve and also help exposure to keratopathy in selected cases.
Surgery in the inactive phase
Once TED becomes inactive and stable, surgery is staged based on what tissue is affected:
- Orbital decompression (for residual proptosis or exposure / prior DON risk)
- Strabismus surgery (for persistent double vision from scarred muscles)
- Eyelid surgery (for lid retraction and exposure)
Conclusion
Thyroid eye disease can affect more than appearance, it can inflame and reshape the eyelids, dry out and damage the cornea, stiffen eye movement muscles, expand tissues behind the eye, and in rare cases compress the optic nerve. The most protective step is early recognition of active disease, especially if symptoms are changing quickly, and taking risk factors like smoking seriously (smoking is strongly linked to higher TED risk and poorer response).
If you notice double vision, rapid bulging, worsening exposure dryness, or any dimming of vision or colour, don’t wait, those can be signs that deeper tissues are involved and timing can protect sight.
FAQs
Is thyroid eye disease the same as Graves’ disease?
Not exactly, Graves’ disease affects the thyroid gland, while thyroid eye disease affects tissues around the eyes, though they commonly occur together. Many people with Graves’ never develop significant eye symptoms, and some people can have TED even when thyroid levels are normal or already treated.
Can thyroid eye disease cause permanent eye damage?
Yes, thyroid eye disease can cause permanent eye damage, especially if exposure damages the cornea or if muscles scar and restrict movement, leading to lasting double vision. The most serious risk is dysthyroid optic neuropathy, where optic nerve compression can threaten vision if not treated quickly.
How do I know if TED is in the active phase?
To determine if TED is in the active phase, doctors use the Clinical Activity Score (CAS), which counts pain and visible inflammatory signs; a CAS of 3 or more on a 7-point scale commonly suggests active disease. Practically, active TED is more redness, swelling, pain on movement, and faster week-to-week change.
Does quitting smoking really help thyroid eye disease?
Yes, quitting smoking really helps thyroid eye disease. Smoking is one of the strongest risk factors linked to TED and worse outcomes. Studies have reported much higher odds of TED in smokers (including an odds ratio of 7.7 in one widely cited analysis).
What treatments protect eye tissues in moderate-to-severe TED?
Treatments that protect eye tissues in moderate-to-severe TED include intravenous steroid regimens for active moderate-to-severe disease, with 4.5 g IV methylprednisolone over 12 weekly infusions described as an optimal regimen in EUGOGO guidance. Other options include immunomodulators and, in selected settings, targeted therapy such as teprotumumab, which showed strong proptosis response rates versus placebo in trials.
